Moors & Cabot’s DexCom DXCM Stock Holding History

Moors & Cabot’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,665	Closed	-$231K	–	886
2024 Q1	$231K	Buy	+1,665	New	+$209K	0.01%	764

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Moors & Cabot's DXCM Position: Q2 2024 in Review

Moors & Cabot sold out of DexCom (DXCM) in Q2 2024, closing a stake of 1,665 shares — an estimated $231K sold.

Moors & Cabot first reported a position in DXCM in Q1 2024 and held it in 1 quarter. The position peaked at $231K in Q1 2024. 999 funds tracked by Wall St. Rank hold DXCM as of Q2 2024.

Moors & Cabot reported no remaining DexCom position as of Q2 2024 after selling out during the quarter.
Moors & Cabot sold 1,665 DexCom shares in Q2 2024, an estimated $231K.
Moors & Cabot first reported a position in DexCom in Q1 2024 and held it in 1 quarter.
Moors & Cabot's DexCom position peaked at $231K in Q1 2024.
999 funds tracked by Wall St. Rank held DexCom as of Q2 2024.

Based on Moors & Cabot's 13F filing for Q2 2024, filed 9 Aug 2024.